These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 6376484)

  • 21. An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.
    Davidson JR; Giller EL; Zisook S; Overall JE
    Arch Gen Psychiatry; 1988 Feb; 45(2):120-7. PubMed ID: 3276281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of bupropion in tricyclic-resistant or intolerant patients.
    Stern WC; Harto-Truax N; Bauer N
    J Clin Psychiatry; 1983 May; 44(5 Pt 2):148-52. PubMed ID: 6406447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder.
    Feiger AD; Heiser JF; Shrivastava RK; Weiss KJ; Smith WT; Sitsen JM; Gibertini M
    J Clin Psychiatry; 2003 Mar; 64(3):243-9. PubMed ID: 12716264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of venlafaxine, trazodone, and placebo in major depression.
    Cunningham LA; Borison RL; Carman JS; Chouinard G; Crowder JE; Diamond BI; Fischer DE; Hearst E
    J Clin Psychopharmacol; 1994 Apr; 14(2):99-106. PubMed ID: 8195464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Valproate as an antidepressant in major depressive disorder.
    Davis LL; Kabel D; Patel D; Choate AD; Foslien-Nash C; Gurguis GN; Kramer GL; Petty F
    Psychopharmacol Bull; 1996; 32(4):647-52. PubMed ID: 8993086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients.
    Schweizer E; Feighner J; Mandos LA; Rickels K
    J Clin Psychiatry; 1994 Mar; 55(3):104-8. PubMed ID: 8071246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
    Mallinckrodt CH; Watkin JG; Liu C; Wohlreich MM; Raskin J
    BMC Psychiatry; 2005 Jan; 5():1. PubMed ID: 15631624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors that influence the outcome of placebo-controlled antidepressant clinical trials.
    Niklson IA; Reimitz PE; Sennef C
    Psychopharmacol Bull; 1997; 33(1):41-51. PubMed ID: 9133750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
    Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
    Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
    Rynn M; Russell J; Erickson J; Detke MJ; Ball S; Dinkel J; Rickels K; Raskin J
    Depress Anxiety; 2008; 25(3):182-9. PubMed ID: 17311303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brofaromine (CGP 11 305 A) in treatment of depression: biological estimation of plasma concentrations.
    Fritze J; Becker T; Ziegler V; Laux G; Riederer P
    Pharmacopsychiatry; 1990 May; 23(3):131-4. PubMed ID: 2374771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of isocarboxazid in hypertensive patients.
    Drapkin A; Goldberger E
    J New Drugs; 1966; 6(4):237-42. PubMed ID: 5338656
    [No Abstract]   [Full Text] [Related]  

  • 34. Platelet MAO inhibition, urinary MHPG, and leukocyte beta-adrenergic receptors in depressed patients treated with phenelzine.
    Sharma RP; Janicak PG; Javaid JI; Pandey GN; Gierl B; Davis JM
    Am J Psychiatry; 1990 Oct; 147(10):1318-21. PubMed ID: 2169208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isocarboxazid. Efficacy and tolerance.
    Davidson J; Turnbull C
    J Affect Disord; 1983 May; 5(2):183-9. PubMed ID: 6222098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between response to phenelzine and MAO inhibition in a clinical trial of phenelzine, amitriptyline and placebo.
    Raft D; Davidson J; Wasik J; Mattox A
    Neuropsychobiology; 1981; 7(3):122-6. PubMed ID: 7231652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of response to monoamine oxidase inhibitors: do they exist?
    Davidson JR; Giller EL; Zisook S; Helms MJ
    Eur Arch Psychiatry Clin Neurosci; 1991; 241(3):181-6. PubMed ID: 1824048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 3-year follow-up of a group of treatment-resistant depressed patients with a MAOI/tricyclic combination.
    Berlanga C; Ortega-Soto HA
    J Affect Disord; 1995 Jun; 34(3):187-92. PubMed ID: 7560546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platelet binding characteristics distinguish placebo responders from nonresponders in depression.
    Sheline YI; Black KJ; Bardgett ME; Csernansky JG
    Neuropsychopharmacology; 1995 Jul; 12(4):315-22. PubMed ID: 7576008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Symptoms of interpersonal sensitivity in depression.
    Davidson J; Zisook S; Giller E; Helms M
    Compr Psychiatry; 1989; 30(5):357-68. PubMed ID: 2676337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.